Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial

The Lancet Oncology

Volumn 18, Issue 8, 2017, Pages 1116-1125

  Faivre Finn, Corinne ^a,b   Snee, Michael ^c   Ashcroft, Linda ^b   Appel, Wiebke ^d   Barlesi, Fabrice ^e   Bhatnagar, Adityanarayan ^f   Bezjak, Andrea ^g   Cardenal, Felipe ^h   Fournel, Pierre ⁱ   Harden, Susan ^j   Le Pechoux, Cecile ^k   McMenemin, Rhona ^l   Mohammed, Nazia ^m   O'Brien, Mary ⁿ   Pantarotto, Jason ^o   Surmont, Veerle ^p   Van Meerbeeck, Jan P ^q   Woll, Penella J ^r   Lorigan, Paul ^a   Blackhall, Fiona ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c St James's Institute of Oncology   (United Kingdom)

^d LANCASHIRE TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^e AIX MARSEILLE UNIVERSITY   (France)

^f UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^g PRINCESS MARGARET HOSPITAL   (Canada)

^h CATALAN INSTITUTE OF ONCOLOGY   (Spain)

ⁱ Institut de Cancérologie Lucien Neuwirth   (France)

^j CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^k INSTITUT GUSTAVE ROUSSY   (France)

^l NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^m BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

ⁿ INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^o UNIVERSITY OF OTTAWA   (Canada)

^p GHENT UNIVERSITY HOSPITAL   (Belgium)

^q ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^r UNIVERSITY OF SHEFFIELD   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ETOPOSIDE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BLEEDING; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONTROLLED STUDY; DEATH; ESOPHAGITIS; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RADIOTHERAPY DOSAGE; RANDOMIZED CONTROLLED TRIAL; SMALL CELL LUNG CANCER; THROMBOCYTOPENIA; TREATMENT DURATION; ADVERSE EFFECTS; CLINICAL TRIAL; INTENTION TO TREAT ANALYSIS; LUNG NEOPLASMS; MULTICENTER STUDY; PATHOLOGY; PROCEDURES; RADIATION DOSE FRACTIONATION; RADIATION PNEUMONITIS; SMALL CELL LUNG CARCINOMA; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY; CISPLATIN; DOSE FRACTIONATION; ESOPHAGITIS; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTENTION TO TREAT ANALYSIS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUTROPENIA; RADIATION PNEUMONITIS; SMALL CELL LUNG CARCINOMA; SURVIVAL RATE;

EID: 85020944773     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(17)30318-2     Document Type: Article

References (21)

1. Govindan, R, Page, N, Morgensztern, D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 24 (2006), 4539–4544.
2. Murray, N, Coy, P, Pater, JL, et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 11 (1993), 336–344.
3. Johnson, BE, Bridges, JD, Sobczeck, M, et al. Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine. J Clin Oncol 14 (1996), 806–813.
4. Turrisi, AT, Kim, K, Blum, R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340 (1999), 265–271.
5. Pignon, JP, Arriagada, R, Ihde, DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 327 (1992), 1618–1624.
6. Warde, P, Payne, D, Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 10 (1992), 890–895.
7. De Ruysscher, D, Pijls-Johannesma, M, Vansteenkiste, J, Kester, A, Rutten, I, Lambin, P, Systematic review and meta-analysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited-stage, small-cell lung cancer. Ann Oncol 17 (2006), 543–552.
8. Fried, DB, Morris, DE, Poole, C, et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol 22 (2004), 4837–4845.
9. Huncharek, M, McGarry, R, A meta-analysis of the timing of chest irradiation in the combined modality treatment of limited-stage small cell lung cancer. Oncologist 9 (2004), 665–672.
10. Pijls-Johannesma, MC, De Ruysscher, D, Rutten, I, Vansteenkiste, J, Lambin, P, Early versus late chest radiotherapy for limited stage small cell lung cancer. Cochrane Database Syst Rev, 1, 2005 CD004700.
11. De Ruysscher, D, Lueza, B, Le Péchoux, C, et al. Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis. Ann Oncol 27 (2016), 1818–1828.
12. Jett, JR, Schild, SE, Kesler, KA, Kalemkerian, GP, Treatment of small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 143:suppl 5 (2013), e400S–e419S.
13. Komaki, R, Khalid, N, Langer, CJ, et al. Penetration of recommended procedures for lung cancer staging and management in the United States over 10 years: a quality research in radiation oncology survey. Int J Radiat Oncol Biol Phys 85 (2013), 1082–1089.
14. Choi, NC, Herndon, JE 2nd, Rosenman, J, et al. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer. J Clin Oncol 16 (1998), 3528–3536.
15. Faivre-Finn, C, Falk, S, Ashcroft, L, et al. Protocol for the CONVERT trial—Concurrent ONce-daily VErsus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status. BMJ Open, 6, 2016, e009849.
16. Zelen, M, Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 4 (1973), 31–42.
17. Oken, MM, Creech, RH, Tormey, DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5 (1982), 649–655.
18. Vallières, E, Shepherd, FA, Crowley, J, et al. International Association for the Study of Lung Cancer International Staging Committee and Participating Institutions. The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 4 (2009), 1049–1059.
19. The National Cancer Institute. Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0). Aug 9, 2009.
20. De Ruysscher, D, Pijls-Johannesma, M, Bentzen, SM, et al. Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol 24 (2006), 1057–1063.
21. Ludbrook, JJ, Truong, PT, MacNeil, MV, et al. Do age and comorbidity impact treatment allocation and outcomes in limited stage small-cell lung cancer? A community-based population analysis. Int J Radiat Oncol Biol Phys 55 (2003), 1321–1330.